Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors

How Investors Are Reacting To Shionogi (TSE:4507) Clinical Trial Results

IDWeek 2026: Shionogi Presents U.S. Analysis of Real-World Data Showing Early Treatment Initiation with Fetroja®/Fetcroja® (cefiderocol) Improved Clinical Outcomes in Patients with Respiratory Infections

Shionogi and F2G’s invasive aspergillosis drug shows long-term benefit

CSL appoints Deborah Waterhouse as CEO & Managing Director

Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal

Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal (NASDAQ:ZVRA)

Shionogi & Co. (SGIOY) Upgraded to Buy: Here's What You Should Know

SGIOY or UTHR: Which Is the Better Value Stock Right Now?

Can Shionogi (TSE:4507) Support Its Price With Earnings After IntraBio?

Shionogi bolsters rare disease portfolio with $2bn IntraBio buyout

GSK-owned ViiV succeeds in late-stage HIV study (GSK:NYSE)

Shionogi acquires rare disease startup IntraBio for $2 billion

Shionogi pays $2B to acquire a rare disease startup

GRFS or SDZNY: Which Is the Better Value Stock Right Now?